SCHEMBL3848738

SCHEMBL3848738

CCOC(=O)c1c(O)c(-c2cc(F)cc(F)c2)nn(Cc2ccccc2Cl)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
MAPT P10636 3/20 0.44
GAA P10253 2/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
USP2 O75604 1/20 0.42
SLC16A3 O15427 2/20 0.41
SLC16A1 P53985 2/20 0.41
MCTS1 Q9ULC4 2/20 0.41
KDM4E B2RXH2 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NLRP3 Q96P20 1/20 0.41
TSHR P16473 2/20 0.40
MEN1 O00255 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3853108 0.93 SLC16A3 (0.45) ALDH1A1MAPTGAALMNAMAPK1
SCHEMBL3849543 0.91 ALDH1A1 (0.47) ALDH1A1MAPTGAALMNACYP1A2
SCHEMBL3849224 0.89 ALDH1A1 (0.50) ALDH1A1MAPTGAALMNAMAPK1
SCHEMBL3853375 0.87 ALDH1A1 (0.48) ALDH1A1MAPTGAALMNACYP1A2
SCHEMBL3847891 0.87 ALDH1A1 (0.41) ALDH1A1LMNAKDM4EL3MBTL1PDE4B
SCHEMBL3846803 0.85 MAPT (0.46) ALDH1A1MAPTGAALMNASLC16A3
SCHEMBL3856473 0.84 SLC16A3 (0.50) ALDH1A1SLC16A3SLC16A1MCTS1KDM4E
SCHEMBL3847266 0.84 EGLN3 (0.51) ALDH1A1MAPTGAALMNACYP1A2
SCHEMBL3845552 0.84 MET (0.45) ALDH1A1MAPTLMNAMAPK1CYP3A4
SCHEMBL3849089 0.82 ALDH1A1 (0.53) ALDH1A1MAPTGAALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
CN-101626685-B N-substituted glycine derivatives: hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2013-03-13 CN disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN ALDH1A1 564/4885MAPT 4802/4885GAA 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.